Recent trends in specialty pharma business model.

Area of Science:

• Pharmaceutical industry trends
• Drug development strategies
• Biotechnology and biopharmaceuticals

Background:

• Traditional big pharma faces challenges like patent cliffs and low R&D productivity.
• Specialty pharma's flexible model drives industry growth.
• Externalization of R&D and corporate venture capital are key strategies for big pharma.

Purpose of the Study:

• To analyze the shift towards specialty pharma and its impact on the pharmaceutical industry.
• To identify preferred targets for licensing and collaboration.
• To explore the strategies and opportunities for specialty pharma in the current landscape.

Main Methods:

• Analysis of industry trends and business models.
• Identification of preferred drug development stages (Biologics, Phase II POC).
• Evaluation of strategies like drug repurposing and orphan drug development.

Main Results:

• Biologics and Phase II proof-of-concept (POC) compounds are favored for collaboration.
• Orphan drugs offer incentives due to streamlined regulatory pathways.
• Specialty medicine, including orphan drugs, is the primary growth driver.

Conclusions:

• Specialty pharma's rise is reshaping the pharmaceutical landscape.
• Collaboration and in-licensing between big pharma and specialty pharma are increasing.
• Understanding intellectual property and regulations is crucial for specialty pharma's global success.